SCHEMBL7798795

SCHEMBL7798795

CCOC(=O)c1cnc2c3c(ccc2c1O)C(=O)C(C(=O)OCC)C=N3

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MAPT P10636 3/20 0.39
TP53 P04637 1/20 0.39
KDM4E B2RXH2 3/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 1/20 0.36
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
POLB P06746 1/20 0.34
RAD52 P43351 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6985515 0.83 KMT2A (0.34) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL6978635 0.82 KMT2A (0.53) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL6982865 0.76 HAVCR2 (0.30)
SCHEMBL7798920 0.75 KMT2A (0.37) KMT2AMEN1RAB9AMAPTGAA
SCHEMBL6982966 0.73 PSMD14 (0.37) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL6985195 0.73 ALDH1A1 (0.42) KMT2AMEN1MAPTTP53KDM4E
SCHEMBL7225483 0.71 ALDH1A1 (0.35) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL6981252 0.70 L3MBTL1 (0.38) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL7803262 0.70
SCHEMBL6200696 0.69 ALDH1A1 (0.62) KMT2AMEN1NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 KMT2A 1250/4885MEN1 2187/4885NPC1 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.